Abstract 117P
Background
Hepatoid adenocarcinoma of stomach (HAS) is a rare subtype of gastric cancer (GC) with hepatocyte-like differentiation and a dismal prognosis. Although HAS has different histological and molecular properties and more aggressive biological behavior, most patients with HAS still receive the same regimen as usual GC. A comprehensive understanding of the molecular properties of HAS may provide insights into personalized diagnosis and treatment, however, this area is under-studied.
Methods
We aimed to explore methylome and transcriptome profiling of HAS in a relatively precise scenario. The laser capture microdissection (LCM) was used to isolate thirty-two formalin fixed paraffin-embedded (FFPE) tissue into gastric adenocarcinoma section (GAC) and hepatocellular-like section (HAS). According to the manufacturer's protocol, DNA-associated methylation sequencing and RNA-associated transcriptome sequencing were performed.
Results
With Laser-Capture Microdissection (LCM) technique, we separate HAS FFPE sample into gastric adenocarcinoma component (GAC) and HAS component. The whole genome RNAseq and methylation sequencing (GMseq) were used to explore HAS expression patterns and methylation modification profile. We found that differentially methylated cytosine was effective in distinguishing GAC from HAS, and stem cell-related gene expression and pathway enrichment were higher in GAC than in HAS. Correspondingly, HAS showed TNFSF15 gene significantly hypermethylation and lower expression features. In addition, in vivo xenograft models derived from TNFSF15 knockout cells showed higher aggressiveness and hepatocyte-like gene expression. Our study sheds light on the critical role of TNFSF15 in HAS transdifferentiation, and intervening methylation of TNFSF15 may be a clinical option to improve prognosis and reduce metastasis.
Conclusions
In summary, we found that the GAC component has the expression features of pluripotent stem cells and mesothelial cells, and the HAS component has the features of hepatoblast and mature hepatocytes. We propose that GAC mesoderm and endoderm dedifferentiation bias TME as the key role to HAS transdifferentiation and TNFSF15 may be a key regulatory factor in this process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (pts) (NeoPele): Analysis of the peripheral immune profile correlated to pathological response
Presenter: Ines Pires da Silva
Session: Poster session 08
134P - Unraveling functionally distinct metabolic programs to predict immunotherapy response in non-small cell lung cancer (NSCLC)
Presenter: Arutha Kulasinghe
Session: Poster session 08
135P - Soluble PD-L1 (sPD-L1) as a predictive biomarker in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in the first-line setting
Presenter: Adrien Costantini
Session: Poster session 08
136P - Circulating hPG80 (WNT pathway activation) as a potential new prognostic/predictive factor of immunotherapy (ICI) efficacy: ONCOPRO prospective study
Presenter: Benoit You
Session: Poster session 08
137P - Long circulating-free DNA fragments predict early-progression (EP) and progression-free survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): A new biomarker
Presenter: Sebastien Salas
Session: Poster session 08
138P - Toward predicting immune checkpoint blockade response in oesophageal squamous cell carcinoma: Integrating tumour and blood characteristics
Presenter: Amelie Franken
Session: Poster session 08
139P - Multimodal prognosis modeling of advanced NSCLC treated with first-line immunochemotherapy: Integrating genomic and microenvironmental data
Presenter: Yi Hu
Session: Poster session 08
140P - Mining metastatic lymph nodes for response to immune checkpoint therapy in non-small cell lung cancer
Presenter: Elena Donders
Session: Poster session 08
141P - Circulating immune cells predict immunotherapy benefit in patients with triple negative breast cancer: Preliminary results from the IRIS study
Presenter: Benedetta Conte
Session: Poster session 08
142P - Exploring tumor mutational burden and frameshift mutations as predictors of immune checkpoint inhibitor efficacy
Presenter: Mai Hoshino
Session: Poster session 08